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The TOR (target of rapamycin) pathway controls cell
growth in response to nutrient availability in eukary-
otic cells. Inactivation of TOR function by rapamycin or
nutrient exhaustion is accompanied by triggering
various cellular mechanisms aimed at overcoming the
nutrient stress. Here we report that in Saccharomyces
cerevisiae the protein kinase C (PKC)-mediated mito-
gen-activated protein kinase pathway is regulated by
TOR function because upon specific Tor1 and Tor2 in-
hibition by rapamycin, Mpk1 is activated rapidly in a
process mediated by Sit4 and Tap42. Osmotic stabiliza-
tion of the plasma membrane prevents both Mpk1 acti-
vation by rapamycin and the growth defect that occurs
upon the simultaneous absence of Tor1 and Mpk1 func-
tion, suggesting that, at least partially, TOR inhibition is
sensed by the PKC pathway at the cell envelope. This
process involves activation of cell surface sensors,
Rom2, and downstream elements of the mitogen-
activated protein kinase cascade. Rapamycin also in-
duces depolarization of the actin cytoskeleton through
the TOR proteins, Sit4 and Tap42, in an osmotically
suppressible manner. Finally, we show that entry into
stationary phase, a physiological situation of nutrient
depletion, also leads to the activation of the PKC path-
way, and we provide further evidence demonstrating
that Mpk1 is essential for viability once cells enter G0.
Rapamycin is an antibiotic macrolide, with a strong antipro-
liferative action in eukaryotic cells. Its target is FK506-binding
protein (FKBP)1 12, a small protein belonging to the FKBP
family of peptidylprolyl isomerases (1, 2). An FKBP12-rapamy-
cin complex is able to bind the TOR proteins (target of rapa-
mycin, also known as FRAP, RAFT, RAPT, or mTOR (3)) and to
block TOR signaling to downstream effectors. The TOR pro-
teins are members of the phosphatidylinositol kinase-related
kinase family, and despite displaying significant homology to
lipid kinases (4), they have been shown to be Ser/Thr protein
kinases (5).
In Saccharomyces cerevisiae cells, the TOR proteins promote
association between the Sit4 and Tap42 proteins under favor-
able nutrient conditions (6). Two other 2A protein phospha-
tases, Pph21p and Pph22p, also associate with Tap42 in a
TOR-dependent rapamycin-sensitive manner (6). The SIT4
gene codes for a Ser/Thr protein phosphatase closely related to
the protein phosphatase 2A family (7, 8) and displays a high
level of identity to human protein phosphatase 6. Tap42 shows
sequence homology to the mammalian 4 protein, which in
turn is able to associate with protein phosphatase 6 (9, 10).
Tap42 can be phosphorylated directly by TOR, and this phos-
phorylation increases Tap42 affinity for the phosphatases (11).
In yeast cells, inhibition of TOR function by rapamycin results
in dissociation of the Sit4-Tap42 complex (6) and in cellular
responses similar to those exhibited in nutrient-starved cells.
These include down-regulation of translation initiation (6), re-
pression of ribosome biogenesis (12), cell cycle arrest (13), in-
duction of autophagy (14), and acquisition of thermotolerance
(6). Both TOR and the Tap42-phosphatase complex are also
involved in the repression of the starvation transcriptional
program (15, 16), which is achieved by preventing the nuclear
translocation of specific transcription factors (17), and in the
Tap42-mediated stabilization of amino acid permeases (18).
Recently, TOR signaling has been shown to control autophagy
via an Apg1 protein kinase complex, although Tap42 has been
proposed not to be involved in this specific signaling (19). Thus,
most of TOR cellular functions imply the regulation of the
Tap42-phosphatase complexes. Based on correlations estab-
lished between the Sit4-Tap42 association state and the phos-
phorylation of downstream effectors, it has been proposed that
Tap42 may inhibit Sit4 phosphatase activity (17, 18), although
no direct target of the phosphatase has been described yet.
The TOR genes were originally identified in yeast by the fact
that certain mutations in them conferred resistance to growth
inhibition by rapamycin (3). The two yeast Tor proteins termed
Tor1 and Tor2, can bind to the FKBP12 homolog (Fpr1)-rapa-
mycin complex in budding yeast. TOR1 and TOR2 display a
high degree of sequence homology. However, although both
regulate the Sit4-Tap42 complex in response to nutrients,
TOR2 plays an additional essential function that is not shared
by TOR1 (20). The TOR2 essential function has been related to
the organization of the actin cytoskeleton (21). A temperature-
sensitive tor2ts mutant displays lower activity levels of the
GTPase exchange factor Rom2 (18), which in turn is needed to
activate the essential Rho1 small GTPase (22). Growth and
actin polarization defects of tor2ts alleles are rescued by high
copy expression of Rho1 or any of the members of the protein
kinase C (PKC)/cell integrity pathway (23), as well as by cell
wall damage-mediated activation of the pathway (22). The PKC
pathway has been proposed to maintain cell integrity by mon-
itoring the cell wall state (for a recent review, see 24). It is
accepted that the PKC pathway senses cell wall damage and
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plasma membrane stress through Mid2 (25) and the Wsc family
of cell surface sensors (26), which would directly transmit the
signal to Rom2 and Rho1 (27). Among other targets, Rho1 can
directly up-regulate the glucan synthase machinery (28) and is
also needed to stimulate Pkc1 protein kinase activity alloster-
ically (29). In turn, Pkc1 activates a module of MAPKs, consti-
tuted by MAPKKK (MAPK kinase kinase) Bck1, the redundant
MAPKKs (MAPK kinases) Mkk1 and Mkk2, and MAPK Mpk1/
Slt2. Mpk1 is phosphorylated on both Thr190 and Tyr192 resi-
dues, thus causing a conformational switch that results in its
activation (30–32).
We have shown recently that deletion of the SIT4 protein
phosphatase gene leads to an increase in the activity of the
PKC/MAPK cell integrity pathway (33). Sit4 is also involved in
mediating rapamycin-sensitive TOR signaling by its associa-
tion with Tap42 in response to nutrients (6). The involvement
of SIT4 in the regulation of both pathways prompted us to
investigate the possible link between rapamycin signaling and
the cell integrity pathway.
EXPERIMENTAL PROCEDURES
Yeast Strains and Gene Disruptions—Yeast strains used in this
study are listed in Table I. Yeast transformations were performed by
the lithium acetate procedure (34). The URA3 marker from Candida
albicans (35) was used to disrupt the WSC1 gene by the one-step
disruption method (36). This method was also employed to disrupt the
MID2 and TOR1 genes with the kanMX4 module (36), whereas the
WSC2 gene was disrupted with the natMX4 module (37).
Media and Growth Conditions—Yeast strains were grown in YPD
medium (2% yeast extract, 1% peptone, 2% glucose). To monitor entry
into stationary phase, cells were grown in selective glucose minimal
medium, SD (0.67% yeast nitrogen base, 2% glucose, and the required
amino acids) (38). Osmotic stabilization was provided where indicated
by adding sorbitol or KCl to a final concentration of 0.8 and 0.5 M,
respectively. Except where stated, cells were grown at 25 °C. To inac-
tivate the temperature-sensitive rho1-104 allele, cells were shifted from
25 to 39 °C for 45 min (39). Rapamycin (from Sigma) was stored at
20 °C as a 1 mg/ml stock solution (90% ethanol and 10% Tween) and
used at a final concentration of 200 ng/ml. Tunicamycin was stored at
20 °C as a 5 mg/ml stock solution (75% methanol) and used at a final
concentration of 2.5 g/ml.
Analysis of Microarray Data—Raw data (16, 40) corresponding to
Mpk1-regulated genes were plotted as a function of time in a Microsoft
Excel worksheet. To maximize inductions and to avoid punctual devi-
ations, data were plotted as a stacked area profile.
Yeast Extracts and Immunoblot Analyses—For Western analysis,
cultures were grown overnight, and cells were harvested by filtration
through 0.22-m Millipore membranes, washed with ice-cold medium,
transferred to Eppendorf tubes, and centrifuged for 15 s at 14,000 rpm.
Total yeast protein extracts were prepared as described by Gallego et al.
(41). The protein concentration in the supernatants was determined by
a Micro DC protein assay (Bio-Rad). Equivalent amounts of total pro-
tein extracts were run on 10% SDS-polyacrylamide gels. The anti-
phospho-p44/p42 antibody (New England Biolabs) was used at a final
dilution of 1:5,000 in TBST buffer, and the anti-GST-Mpk1 antibody
(39, 42) at a 1:2,000 dilution in the presence of 5% fat milk. Horseradish
peroxidase-linked anti-rabbit secondary antibody (NA931, Amersham
Biosciences) was used at a 1:10,000 dilution and incubated in TBST
buffer containing 1% fat milk for the anti-phospho-Mpk1 and 0.25% fat
milk for the anti-GST-Mpk1 primary antibody. Chemoluminescent de-
tection was performed using the Supersignal Substrate (Pierce) in a
Lumi-Imager equipment (Roche Molecular Biochemicals).
Actin Staining—Cells were fixed in 4% formaldehyde for 10 min,
centrifuged at 3,000 rpm 5 min, and fixed overnight in phosphate-
buffered saline plus 4% formaldehyde. Cells were washed once with
phosphate-buffered saline containing 10 mM ethanolamine, and once
more with phosphate-buffered saline. For F-actin staining, rhodamine-
phalloidin (from Sigma; stored as a 6.6 M solution at 20 °C in meth-
anol) was used at a final concentration of 0.6 M. Cells were stained for
at least 2 h in the dark and washed five times with phosphate-buffered
saline before resuspending in mounting solution. All centrifugations
were performed at 3,000 rpm.
RESULTS
The PKC Pathway Is Activated in Response to Rapamycin
Treatment and upon Entry into Stationary Phase—To test
whether rapamycin had any effect on the activity of the PKC
pathway, we performed Western blot analysis of total cell ex-
tracts using anti-phospho-p44/42 MAPK antibodies. These an-
tibodies specifically recognize the doubly phosphorylated form
of Mpk1 and allow accurate monitoring of Mpk1 activity (26,
39). Rapamycin was added to wild type cultures growing expo-
nentially at 25 °C in rich medium (YPD), and samples were
taken at the indicated times (Fig. 1A). We observed a very rapid
increase in the amount of the active Mpk1 form in response to
rapamycin, already detectable after 15 min of treatment. Max-
imum levels of Mpk1 activity were reached after 45 min and
remained high for the duration of the experiment (60 min). The
induction of Mpk1 activity was not the result of an increase in
the Mpk1 protein levels, which remained constant throughout
the experiment (Fig. 1A), as observed after probing the same
extracts with anti-Mpk1 polyclonal antibodies.
TABLE I
Yeast strains used in this work
Strain Relevant genotype Refs.
CML128 MAT leu2–3,112 ura3–52 trp1 his4 can1r 41
CML125 MAT As CML128 33
JA-110 CML128 sit4trp1 75
MML382 CML128 wsc1caURA3 33
MML384 CML128 wsc2natMX4 33
MML387 CML128 mid2kanMX4 33
MML392 CML128 wsc1caURA3 wsc2natMX4 33
MML393 CML128 wsc1caURA3 mid2kanMX4 33
MML391 CML125 rom2kanMX4 This study
MML200 CML128 bck1kanMX4 33
CML399 CML128 mpk1URA3 33
HNY21 MATa ura3 leu2 trp1 his3 ade2 rho1–104 76
JK9–3da MATa leu2–3,112 ura3–52 rme1 trp1 his4 GAL 3
JH11–1c JK9–3da TOR1–1 3
JH12–17b JK9–3da TOR2–1 3
MML304 MAT pkc1LEU2(pBCK1–20) 33
MML378 JK9–3da tor1kanMX4 This study
MML380 JK9–3da TOR2–1 tor1kanMX4 This study
MML447 CML128 tor1kanMX4 mpk1URA This study
MML448 CML128 tor1kanMX4 This study
CY4907 W303 MATa ura3–1 leu2–3,112 his3–11,15 trp1–1 ade2–1 can1–100
tap42TRP1 SSD1- {TAP42 on LEU2/CEN}
6
CY4908 W303 MATa ura3–1 leu2–3,112 his3–11,15 trp1–1 ade2–1 can1–100
tap42TRP1 SSD1- {tap42–11 on LEU2/CEN}
6
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Two related MAPKs, Fus3 and Kss1, are also recognized in
their active, doubly phosphorylated state by the same antibody
(43, 44). However, no significant change in their activity was
detected after the addition of rapamycin (Fig. 1, A and B). The
latter suggests that rapamycin-mediated MAPK activation is
specific for Mpk1.
The transcripts up-regulated by Mpk1 activation have been
described recently using whole-genome approaches and com-
prise mostly cell wall and stress-responsive genes (45). The
induction of all of them is expected to occur under any stress
that activates Mpk1, including rapamycin treatment. To check
the validity of this hypothesis, we carried out an in silico study
of the behavior of Mpk1-regulated genes under different envi-
ronmental perturbations that either induce or do not affect
Mpk1 activity. Data on Mpk1-regulated genes was extracted
from previously published works (40) and plotted as a function
of time (Fig. 1C). As expected, Mpk1-regulated genes are in-
duced by heat shock and hypotonic shock, situations that give
rise to Mpk1 activation, but not by hydrogen peroxide or men-
adione treatment (Fig. 1C and data not shown). In a further
step, we carried out an analogous study on other published
data (16) to check whether the same group of genes was also
induced upon rapamycin treatment. As shown in Fig. 1C, ex-
pression of Mpk1-regulated genes is induced by rapamycin
treatment in a fashion that correlates with the increase in
Mpk1 activity (Fig. 1, A and C), although different concentra-
tions of the inhibitor were used in each experiment. Overall,
these observations evidence that the pattern of Mpk1-regu-
lated gene expression serves as a good marker of Mpk1 activity.
Moreover, because all of those genes are up-regulated by rapa-
mycin, it shows that the signal from rapamycin to Mpk1 is
transmitted to substrates downstream from this kinase, lead-
ing to the transcriptional induction of Mpk1-regulated genes.
The TOR proteins have been proposed to be central sensors
of the quality of carbon and nitrogen sources (46), and rapamy-
cin has been reported to cause effects similar to those exhibited
by nutrient-starved cells. Besides, cells in stationary phase
display phenotypes similar to those caused by rapamycin (6).
Thus, we reasoned that cells entering stationary phase could
also induce Mpk1 activity, as observed when TOR proteins are
blocked by rapamycin (Fig. 1A). Wild type cells were inoculated
in fresh minimal medium, and samples were collected at the
times indicated. As shown in Fig. 1D, Mpk1 became strongly
activated as cells progressively entered into stationary phase
(2–4 days) and became less active at later time points. The
increase in Mpk1 activity was not caused by changes in the
levels of the Mpk1 protein, as checked with anti-Mpk1 poly-
clonal antibodies (Fig. 1D). Moreover, although entry into sta-
tionary phase does not affect viability in wild type cultures,
mpk1 mutant cells rapidly lost viability upon exit from expo-
nential growth (Fig. 1E). In a genomewide screen for genes
whose deletion results in alterations on the growth response to
rapamycin, it has been reported that both MPK1 and SWI6
(whose product is a Mpk1 target) confer rapamycin hypersen-
sitivity when deleted (47). Other authors have shown recently
that an intact PKC pathway is needed to maintain viability
upon nutritional deprivation (48). These results, together with
ours, suggest that Mpk1 activation, and the subsequent induc-
tion of its target genes, is essential for cells to remain viable
once they enter stationary phase or are treated with
rapamycin.
Both TOR1 and TOR2 Signaling Blockages Mediate Mpk1
Activation in Response to Rapamycin—To prove the direct in-
volvement of members of the TOR pathway in mediating rapa-
mycin signaling to Mpk1, we checked the behavior of rapamy-
cin-resistant TOR mutants. TOR1-1 and TOR2-1 bear,
respectively, chromosomal alleles of TOR1 and TOR2 which
are insensitive to the immunosuppressant drug because their
products cannot interact with the Fpr1-rapamycin complex.
The JK9-3da wild type strain induced Mpk1 phosphorylation
with kinetics identical to those of the CML128 wild type strain
used above (Figs. 1A and 2A). However TOR1-1 cells displayed
no change in Mpk1 activity in response to rapamycin treat-
ment, whereas in TOR2-1 cells a mild activation was still
detected (Fig. 2A). The results clearly indicate that Tor1 inhi-
bition mediated by rapamycin signals to Mpk1 inducing its
FIG. 1. Mpk1 activity is induced by rapamycin treatment and
upon entry into stationary phase. A, time course of Mpk1 activation
in response to rapamycin. Mid-log cultures of wild type (CML128) cells,
growing exponentially in YPD medium at 25 °C, were treated with
rapamycin to a final concentration of 200 ng/ml. Samples were taken at
the indicated times. Western blots were done using anti-phospho-p44/
p42 to detect Mpk1, Kss1, and Fus3 double phosphorylation, and anti-
Mpk1 to quantify total amounts of Mpk1 protein. B, rapamycin-medi-
ated MAPK activation is specific for Mpk1. MAPK phosphorylation
levels from A were quantified, relativized to 1 at time 0 for each MAPK,
and plotted as a function of time. C, induction of Mpk1-regulated genes
by rapamycin treatment. Raw data corresponding to the expression of
Mpk1-regulated genes upon heat shock from 25 to 37 °C (40), 0.3 mM
hydrogen peroxide treatment (40), and 100 nM rapamycin treatment
(16) were plotted as a function of time. Mpk1-regulated genes comprise
BGL2, CHS3, CIS3, CRH1, CWP1, DFG5, FKS1, FKS2, HSP150,
MLP1, PIR1, PIR3, PST1, SEC28, SED1, SLT2 (MPK1), SSR1,
YIL117C, YLR194C, YMR295C, and YNL085C. D, induction of Mpk1
activity upon entry into stationary phase. Wild type cells were expo-
nentially grown in minimum medium at 25 °C. At an A600 of 0.3, a
sample was collected to serve as the time 0 reference, and further
samples were recovered at the indicated days. Immunoblots using anti-
phospho-p44/p42 and anti-Mpk1 antibodies in the same protein ex-
tracts were performed as in A. E, loss of viability of mpk1 cells upon
entry into stationary phase. Cell viability was determined for wild type
and mpk1 cells in the same cultures as in D. The data shown are
representative of three independent experiments.
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activity. Therefore, activation of the MAPK is not the result of
a direct cell wall damage effect caused by rapamycin. We hy-
pothesized that the slight Mpk1 activation still observed in
TOR2-1 cells could be the result of the rapamycin-mediated
blockage of a fully inhibitable Tor1 protein. Thus, inhibition of
Tor2 in wild type cells could still contribute to rapamycin
signaling to Mpk1. Support for this hypothesis is the observa-
tion that Fpr1-rapamycin binding to Tor1 occurs at 10-fold
lower rapamycin concentrations compared with those neces-
sary to bind to Tor2 (49); hence, the inhibitory complex has
more affinity for Tor1 than for Tor2.
To test whether Tor2 inhibition by rapamycin is also in-
volved in the induction of the PKC pathway, we deleted the
TOR1 gene in both the wild type and the TOR2-1 strains, and
the levels of Mpk1 activation were checked in the single and
double mutants. The tor1 mutant displayed activation of
Mpk1 in response to rapamycin treatment (Fig. 2A), although
the induction was less pronounced than in wild type cells. This
result clearly indicates that in these conditions Tor2 inhibition
by rapamycin mediates induction of Mpk1 activity. Further-
more, no increase in the activation of the MAPK was detectable
in tor1 TOR2-1 double mutant cells after addition of the drug
(Fig. 2A). In light of these results, we propose that either Tor1
or Tor2 inhibition by rapamycin can mediate Mpk1 activation.
Interestingly, tor1 mutant cells, which may be compromised
for TOR function (because they rely on the single TOR2 gene),
displayed higher levels of both basal and induced Mpk1 activity
than wild type cells, which suggests that partial elimination of
TOR function leads to a constitutive increased activation of
Mpk1 (as rapamycin does). Taken together, these data show
that a block in TOR function may act by up-regulating the PKC
pathway.
TAP42 and SIT4 Mediate Rapamycin Signaling to Mpk1—
An active TOR pathway promotes the association of the Tap42
subunit with the protein phosphatase 2A and Sit4 (6). There-
fore, we tested whether TAP42 is also involved in mediating
rapamycin signaling to Mpk1. The tap42-11 allele is known to
be both temperature-sensitive and rapamycin-resistant at the
permissive temperature (6). In contrast to its isogenic wild type
strain, cells carrying the tap42-11 allele displayed no induction
of Mpk1 activity after the addition of rapamycin at the permis-
sive temperature, although the exponential levels of the MAPK
activity were remarkably higher than those determined in wild
type cells (Fig. 2B). Surprisingly, the isogenic wild type strain
(W303 background) displayed higher levels of basal Mpk1 ac-
tivity than the CML128 or JK9-3da strains, also used in this
study, and although Mpk1 activity was induced by rapamycin,
the up-regulation was not as pronounced as in the other two
backgrounds. These results support the fact that Tap42 is also
involved in the signaling to the PKC pathway which occurs as
a consequence of TOR inhibition.
SIT4, one of the closest TOR downstream effectors, nega-
tively modulates the activity of the Pkc1/MAPK pathway (33).
We therefore checked the possible implication of SIT4 in me-
diating rapamycin signaling to Mpk1. As described previously,
sit4 mutant cells exhibited higher basal levels of Mpk1 acti-
vation than its isogenic wild type strain, but no change in Mpk1
activity levels was detected in the mutant strain after the
addition of rapamycin (Fig. 2C). Mpk1 activity was monitored
in a longer time course to check that its induction did not occur
at later time points. This result suggests that SIT4, as shown
above for TAP42, is involved in rapamycin-mediated induction
of Mpk1. It is worth noting that mutation in either TAP42 or
SIT4 (as well as in tor1 cells) resulted in a constitutive in-
crease in the basal levels of Mpk1 activity relative to their
isogenic wild type strains, which suggests that TOR and
TAP42, as we have shown recently for SIT4 (33), act negatively
on Mpk1 activity under normal growth conditions.
The Signaling between the TOR and the PKC Pathways
Takes Place at a Level Upstream from Rho1—In a further step,
we attempted to elucidate the level at which the cross-talk
between the TOR and PKC pathways occurs. Thus, we ana-
lyzed the response to rapamycin treatment in mutants of the
cell integrity pathway. As expected, neither bck1 nor pkc1
mutant cells showed detectable basal levels of Mpk1 phospho-
rylation, and they were completely insensitive in their response
to rapamycin treatment with respect to Mpk1 activation (Fig.
FIG. 2. Tor1, Tor2, Sit4, and Tap42 mediate Mpk1 activation in
response to rapamycin. A, Mpk1 activation upon rapamycin treat-
ment depends on both TOR1 and TOR2 genes. Exponential cultures of
wild type (wt) (JK9-3da), TOR1-1 (JH11-1c), TOR2-1 (JH12-17b), tor1
(MML378), and tor1TOR2-1 (MML380) cells growing in YPD at 25 °C
were treated with rapamycin to a final concentration of 200 ng/ml.
Samples were taken at the indicated times and processed for analysis
by Western blotting, using anti-phospho-p44/p42 to detect Mpk1 phos-
phorylation, as in Fig. 1A. Phosphorylation levels were quantified as in
Fig. 1B and relativized to 1 at time 0 for each strain. B, TAP42 mediates
Mpk1 activation in response to rapamycin. Wild type (CY4907) and
tap42-11 (CY4908) cells were grown exponentially and treated with
rapamycin as in A. C, Sit4 is needed for rapamycin-induced Mpk1
activation. Wild type (CML128) and sit4 (JA-110) mutant cells were
grown exponentially and treated with rapamycin. Samples were taken
at the indicated times and processed for immunoblotting as in A. In all
cases in A–C, anti-Mpk1 immunoblot analysis of the same extracts was
performed to verify that an equal amount of Mpk1 was present in each
lane (not shown).
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3A and data not shown). These results suggest that the signal-
ing from TOR proteins goes through the various elements of the
PKC pathway to activate Mpk1, the last kinase of the cascade.
To test this, we used a strain deleted for PKC1 bearing the
BCK1-20 allele, which constitutively activates Mpk1 (33). In
this strain, all of the activating signal coming from the up-
stream elements of the pathway become blocked by the absence
of Pkc1. According to our hypothesis, rapamycin treatment
would not provoke additional Mpk1 activation above the basal
levels detected at 25 °C. Alternatively, if there existed a paral-
lel activating pathway from the TOR proteins to Mpk1, inde-
pendently on the cell integrity cascade, we would expect rapa-
mycin to induce Mpk1 activity. As shown in Fig. 3A,
inactivation of TOR function by rapamycin treatment induced
Mpk1 activation in a wild type strain carrying the BCK1-20
allele, whereas in the pkc1 background harboring the
BCK1-20 allele no induction of Mpk1 double phosphorylation
was observed in such conditions. Taken together, from the
above results we propose a model in which rapamycin-induced
signaling to Mpk1 is conveyed by the Pkc1/MAPK module.
Rho1 is a small GTPase that acts as an essential element in
the signaling cascade from the cell surface to Mpk1 (39). Be-
cause its deletion results in lethality, we made use of the
temperature-sensitive rho1-104 allele to analyze its implica-
tion in transducing the signal from rapamycin to Mpk1. Rho1-
104 was inactivated by a temperature shift to 39 °C, which led
to a decrease in the levels of Mpk1 activation (lane 4 in Fig. 3B).
After 45 min of inactivation, rapamycin was added to half of the
culture, and the other half was used as an untreated control.
Samples from both cultures were taken for Western analysis.
Although rapamycin was able to activate Mpk1 at 25 °C, shift-
ing the culture to 39 °C completely abolished its ability to
activate the pathway (Fig. 3B). By contrast, wild type cells
were able to activate Mpk1 by rapamycin treatment further
after being shifted at 39 °C (data not shown). Therefore, Rho1
is also involved in rapamycin signaling from the TOR proteins
to Mpk1.
The activity of small G proteins is tightly regulated, and
several elements have been shown to modulate them (50).
Among all of the regulatory elements controlling Rho1, the best
characterized is Rom2 (51), which may transduce the signal
from the cell surface sensors to Pkc1 via Rho1 (Fig. 3, A and C).
In contrast to the role played by downstream elements in the
PKC pathway, ROM2 seemed to be partially involved in rapa-
mycin signaling to Mpk1; a rom2 mutant strain displayed
reduced basal levels of Mpk1 activity, but the MAPK was only
partially induced in response to rapamycin (8-fold induction
during the first 30 min of incubation in rapamycin in the
mutant strain, in contrast to 13-fold induction in the wild type
strain; Fig. 3A). However, a rom2 mutant strain has been
shown to retain 60% of GTP binding to Rho1 (27), which sug-
gests that the coordinated action of other GTPase exchange
factors for Rho1 (such as Rom1, Bem4, or Tus1) may be respon-
sible for Mpk1 activation after the addition of rapamycin in the
rom2 mutant strain. Moreover, the inactivation of GTPase-
activating proteins for Rho1 may also play a role in rapamycin
signaling to Mpk1.
A Blockage of TOR Function Activates Cell Surface Sensors
in an Osmotic Suppressible Manner—The MID2 gene, coding
for a transmembrane protein proposed to act as a cell surface
sensor, has been described to block activation of the PKC path-
way when deleted (25, 39, 52, 53). WSC1 codes for another class
of cell surface sensor and is thus another possible mediator of
rapamycin signaling to Mpk1 (26). Deletion of either WSC1 or
MID2 provoked a notable reduction in the basal signal of Mpk1
activity compared with wild type cells (Fig. 3A). In addition, the
FIG. 3. The PKC/MAPK module, Pkc1, and Rho1 mediate Mpk1
activation in response to rapamycin. A, upstream components in
the PKC pathway transmit the signal from rapamycin. Exponential
cultures of wild type (wt) (CML128), wsc1mid2 (MML393), wsc1
(MML382), mid2 (MML387), bck1 (MML200), pkc1/pBCK1-20
(MML304), and CML128/pBCK1-20 cells growing in YPD at 25 °C were
treated with rapamycin to a final concentration of 200 ng/ml. Samples
were taken at the indicated times and processed for analysis by West-
ern blotting, using anti-phospho-p44/p42 to detect Mpk1 phosphoryla-
tion, as in Fig. 1A. Phosphorylation levels were quantified as in Fig. 1B
and relativized to 1 at time 0 for each strain. B, a functional Rho1 is
needed to transmit the signal from rapamycin to Mpk1. Exponential
cultures of rho1-104 cells (HNY21) growing in YPD at 25 °C (lane 1)
were either treated with rapamycin to a final concentration of 200 ng/ml
(lanes 2 and 3) or shifted to 39 °C to inactivate Rho1. After 45 min at the
restrictive temperature (lane 4), the culture was spliced in two and kept
at 39 °C. Half of the culture served as a control (lanes 5 and 7), and the
rest was treated with rapamycin to a final concentration of 200 ng/ml
(lanes 6 and 8). Samples were taken at the indicated times for Western
blot analysis. C, scheme of the components of the PKC/cell integrity
pathway. In A and B, anti-Mpk1 immunoblot analysis of the same
extracts was performed to verify that an equal amount of Mpk1 was
present in each lane (not shown).
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induction of MAPK phosphorylation after rapamycin treatment
was partially impaired in both individual mutants (induction
reduced to about half of that in wild type cells after 30 min of
rapamycin treatment in wsc1 cells and even lower in the
mid2 strain). Moreover, the double wsc1mid2 mutant
strain led to a more marked effect on the basal and induced
Mpk1 activity in the presence of the drug, and the induction at
30 min was reduced to one-third relative to wild type cells (Fig.
3A). These results indicate that there is a partial dependence
on the Wsc1 and Mid2 sensors for rapamycin signaling to the
PKC pathway. However, because Wsc proteins have been
shown to act cooperatively and to overlap in function (26), we
cannot discard the possibility that the whole family of Wsc
sensors contributes to rapamycin-mediated activation of Mpk1.
Activation of Wsc sensors can occur in response to a block in
the secretory pathway caused by tunicamycin or thermosensi-
tive mutations in the SEC genes (54). However, the effects that
problems in secretion have on Mpk1 activity are still contra-
dictory (54–56). We checked whether a block in secretion
caused by tunicamycin treatment paralleled Mpk1 activation
in response to rapamycin. The kinetics of Mpk1 activation
differed totally between both treatments. Whereas tunicamy-
cin caused only a slight increase in Mpk1 activity at the time
points tested, rapamycin provoked a much more intense and
rapid activation of the MAPK (Fig. 4A). In view of these results,
we suggest that rapamycin may not be acting on cell surface
sensors by halting secretion, at least not at the same level as
tunicamycin does.
Because Wsc and Mid2 sensors have also been proposed to
sense changes in the yeast cell wall and plasma membrane, we
wondered whether inhibition of TOR function by rapamycin
induced some kind of cell envelope stress. Addition of 0.8 M
sorbitol to the growing medium has been shown to prevent the
activation of the PKC pathway by insults infringed on the cell
envelope (53, 57). When rapamycin treatment was performed
in cultures osmotically stabilized with sorbitol, the induction of
the pathway was severely impaired (Fig. 4B). Similar results
were obtained using 0.5 M KCl as an osmotic stabilizer (Fig.
4B). Thus, rapamycin-mediated inhibition of TOR function
triggers activation of the PKC pathway by means that are
suppressible by addition of an osmotic stabilizer to the growing
culture. Because increasing the external osmolarity is pre-
dicted to relieve the osmotic gradient across the cell membrane,
these results suggest that changes induced by rapamycin may
be taking place on the yeast envelope, either on the cell wall or
on the plasma membrane. However, we have detected no in-
crease in zymoliase sensitivity in rapamycin-treated cells, but
rather a slight increase in resistance to cell wall digestion (data
not shown). Thus, rapamycin may not be inducing Mpk1 activ-
ity by weakening the cell wall.
To understand the above results better, we constructed a
tor1mpk1 double mutant. We reasoned that a lack of TOR
function may either trigger damage in the cell envelope or
alternatively affect its structure in such a way that the cell
requires a functional PKC pathway to compensate for those
changes. In Fig. 4C we can observe that the tor1mpk1 double
mutant, compared with both single ones, displayed a growth
defect already at the permissive temperature 25 °C, which
was more severe at 37 °C. Interestingly, the problems in
tor1mpk1 cell growth were totally rescued upon the addition
of an osmotic stabilizer (Fig. 4C). These results support our
hypothesis that TOR inhibition by rapamycin triggers a signal
that, at least in part, is sensed at the cell envelope and then
activates the cell integrity pathway.
The Actin Cytoskeleton Becomes Disorganized in Response to
Rapamycin Treatment—As shown above, rapamycin inhibition
of both Tor1 and Tor2 function leads to the activation of the
PKC pathway probably by inducing cell wall or plasma mem-
brane stress. Several stresses have been described to induce
the depolarization of the actin cytoskeleton (58, 59), and it has
been shown that this phenotype is specific and not caused by a
halt in cell growth (60). Therefore, we sought to determine
whether rapamycin inhibition of the TOR shared function also
affected the organization of the actin cytoskeleton. The actin
cytoskeleton became disorganized after 45 min of rapamycin
treatment (data not shown), and complete depolarization was
achieved within the 1st h of incubation in rapamycin in all of
the strain backgrounds used in this study (Fig. 5 and data not
shown). Both TOR1-1 and TOR2-1 efficiently suppressed the
actin cytoskeleton depolarization phenotype (Fig. 5 and data
not shown). The SIT4 deletion, and to a lesser extent the
FIG. 4. Cell signaling from TOR to Mpk1 is sensed at the cell
envelope and suppressed upon osmotic stabilization. A, a secre-
tion block caused by tunicamycin treatment does not parallel rapamy-
cin-mediated activation of Mpk1. Exponentially growing wild type cells
(CML128) in YPD at 25 °C were treated with rapamycin or tunicamycin
to a final concentration of 200 ng/ml or 2.5 g/ml, respectively. Samples
were taken at the indicated times. B, osmotic stabilization prevents
activation of Mpk1 by rapamycin. Wild type cultures (CML128) were
grown overnight at 25 °C in YPD alone or in YPD supplemented with
either 0.8 M sorbitol or 0.5 M KCl to exponential phase. Rapamycin was
added at time 0, and samples from each of the three cultures were taken
at the indicated times for Western blot analysis. C, the cell growth
defect provoked by the simultaneous absence of Mpk1 and Tor1 is
rescued upon osmotic stabilization. Serial dilutions of CML128, mpk1,
mpk1 tor1, and tor1 exponentially growing cultures were plated
into YPD and YPD plus 1 M sorbitol and grown at 25 and 37 °C; wt, wild
type. In A and B, anti-Mpk1 immunoblot analysis of the same extracts
was performed to verify that an equal amount of Mpk1 was present in
each lane (not shown).
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tap42-11 allele, also suppressed the actin cytoskeleton depolar-
ization process, albeit more poorly than in the TOR1-1 and
TOR2-1 rapamycin-resistant alleles (Fig. 5). These results in-
dicate that the inhibition of the rapamycin-sensitive TOR
shared function also affects the organization of the actin cy-
toskeleton. It has been described that mutations in WSC1 and
ROM2 genes severely impair depolarization of the actin cy-
toskeleton in response to various cell wall stresses, otherwise
known to induce depolarization in wild type cells (59).2 We
observed that both WSC1- and ROM2-deleted cells displayed a
marked resistance to depolarize the actin cytoskeleton in re-
sponse to rapamycin (Fig. 6), which suggests that both WSC1
and ROM2 also mediate the signal to the actin cytoskeleton.
Moreover, osmotic stabilization by the addition of 0.8 M sorbitol
to the growing medium also prevented depolarization of the
actin cytoskeleton. These results, together with those shown in
Figs. 3 and 4, suggest that inhibition of TOR function rapidly
affects the activity of cell surface sensors by creating cell wall
or plasma membrane stress.
DISCUSSION
We have shown that rapamycin-mediated blockage of TOR
function leads to the up-regulation of the Mpk1 MAPK in all
four of the strain backgrounds used in this study. Thus, TOR
function negatively affects the activity of the PKC pathway,
probably by preventing plasma membrane stress (Fig. 7). We
have also presented evidence demonstrating that rapamycin-
induced activation of Mpk1 is mediated by the TOR effectors
Tap42 and Sit4 and takes place upstream in the cell integrity
pathway, in a process that may involve activation of cell sur-
face sensors.
TOR function has been reported to control cell growth in
response to nutrient signals in eukaryotic cells (for review, see
Refs. 61 and 62). In yeast, it has been suggested, based on
genetic interactions between cell surface sensors and mutants
in the protein kinase A pathway, that the cell integrity path-
way would also be related to nutrient sensing via the Ras/
cAMP pathway (26). BCK1 kinase was also initially cloned as a
2 J. Torres, E. Herrero, and M. A. de la Torre-Ruiz, unpublished
observations.
FIG. 5. TOR genes and their downstream effectors SIT4 and
TAP42 mediate actin cytoskeleton depolarization in response to
rapamycin treatment. Cultures of wild type (wt) (JK9-3da), TOR1-1
(JH11-1C), sit4 (JA-110), and tap42-11 (CY4908) cells were incubated
up to logarithmic phase in YPD at 25 °C, and rapamycin was added to
a final concentration of 200 ng/ml. At the times indicated, samples were
removed, fixed, and processed for actin staining. The parental wild type
strains of sit4 and tap42-11 (CML128 and CY4907, respectively) un-
derwent the same kinetics of actin depolarization as JK9-3da (not
shown).
FIG. 6. Rom2 and upstream components in the PKC pathway
mediate actin cytoskeleton depolarization in response to rapa-
mycin treatment in a sorbitol-suppressible manner. Cultures of
wild type (wt) (CML128), rom2 (MML391), and wsc1 (MML382) cells
were incubated up to logarithmic phase in YPD (or YPD supplemented
with 0.8 M sorbitol) at 25 °C, and rapamycin was added to a final
concentration of 200 ng/ml. At the indicated times, samples were re-
moved, fixed, and processed for actin staining.
FIG. 7. Model for TOR signaling to the PKC pathway. TOR
function promotes association of Sit4 and Tap42 (6), and this may lead
to the down-regulation of the PKC pathway. Inactivation of TOR func-
tion by rapamycin treatment or upon entry into stationary phase causes
the dissociation of the complex and the induction of the pathway in a
process that may involve induction of plasma membrane stress and, in
different degrees, all members of the PKC signaling cascade.
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gene with a Ras/cAMP-independent role in nutrient sensing
(63), and both mutants in BCK1 and WSC1 have been shown to
display defects in cell cycle arrest upon nutrient deprivation
(64, 65). The connection that rapamycin establishes between
TOR and Mpk1 provides new evidence for a role of the cell
integrity pathway in the nutrient stress response. Situations of
limited nutrient availability, such as nitrogen starvation, spor-
ulation, and entry into stationary phase, eventually affect re-
modeling of the cell wall, and regulatory mechanisms affecting
PKC activity may play a central role in all of them. Cells that
have entered into stationary phase or that have been treated
with rapamycin acquire thicker cell walls and display thermo-
tolerance (6, 66). Both processes are dependent, at least in
heat-shocked cells, upon the previous induction of Mpk1 activ-
ity (53). In fact, here we show that Mpk1 is activated by both
rapamycin and upon entry into stationary phase. This activa-
tion may be crucial for thermotolerance acquisition and for
inducing changes in cell wall structure. Furthermore, cells
deleted for MPK1 lose viability when entering stationary
phase. Also, as reported previously by other investigators, an
MPK1-deleted strain is hypersensitive to rapamycin (47). Thus,
Mpk1 seems to have a broader role beyond its known function
in response to cell wall damage, and its activation may be
essential to maintain cell viability once the nutrient supply is
exhausted.
The observation that Mpk1 is activated when cells enter
stationary phase raises the question about the nature of the
signal monitored by TOR which eventually induces the PKC
pathway. Although other types of signal being sensed by the
cells cannot be discarded, we hypothesize that depletion of
some nutrient(s) may lead to the up-regulation of Mpk1 activ-
ity. However, we have not detected significant changes in the
activity of the PKC pathway (measured by Mpk1 activation) in
cells undergoing nitrogen deprivation, amino acid starvation,
or glucose depletion (data not shown). Thus, exhaustion of any
other element(s) could be the event that triggers Mpk1 activa-
tion when cells enter G0. We propose that TOR function main-
tains the signal(s) that prevent the cell integrity pathway from
being activated when cells grow under favorable nutrient
conditions.
Yeast cells have two TOR genes, TOR1 and TOR2. It has
been proposed that the TOR pathway has two essential func-
tions (20), one of which is shared by TOR1 and TOR2. The
other function only depends on TOR2, is not inhibited by ra-
pamycin, and is related to the polarization of the actin cytoskel-
eton through the cell integrity pathway (21–23). Up-regulation
of the PKC pathway in response to TOR inhibition results from
a block of the TOR shared function because it is sensitive to
rapamycin, and it is mediated by both TOR1 and TOR2. Al-
though it remains to be determined whether the TOR2 essen-
tial function also impinges on Mpk1 activity, it seems that both
the TOR shared and the TOR2 essential function may be di-
rectly or indirectly affecting the PKC pathway. The sharing of
common regulatory elements of both TOR functions has been
suggested previously (67) because overexpression of PLC1 or
MSS4 (coding for phospholipase C and a phosphatidylinositol
4-phosphate 5-kinase, respectively) suppresses not only muta-
tions in the TOR2 essential function but also mutants defective
in the TOR shared function, suggesting that TOR regulates two
related signaling pathways.
Our results indicate that cell surface sensors contribute to
Pkc1 signaling when TOR activity is affected. We have shown
that wsc1, mid2, and rom2 cells partially suppress induc-
tion of the PKC pathway in response to rapamycin. We propose
two interpretations for the above results. (i) The fact that all of
those genes display redundancy with their functional homologs
might explain why the single deletants do not totally abolish
rapamycin-dependent activation of Mpk1 and why simultane-
ous deletion of WSC1 and MID2 has an additive effect in the
blockage of rapamycin signaling to Mpk1. (ii) In addition to this
mechanism, other entries to the upper elements upstream from
Pkc1 (namely, Rom2, Rho1) could be functioning from the Sit4-
Tap42 complex and thus also contribute to activate Mpk1. We
have also shown that both rom2 and wsc1 cells partially
block the actin depolarization process. Rapamycin signaling to
cell surface sensors most probably diverges to actin organiza-
tion and Mpk1 activation independently. As expected from
previous reports (59), Rom2 may participate in both. However,
the effects of the PKC pathway in polarity signaling are not
clear: some rho1 alleles and mutations in MPK1 depolarize the
actin cytoskeleton (23, 68), whereas hyperactivation of Rho1
and Pkc1 induces depolarization of the actin cytoskeleton (59),
and rom2 cells display hyperpolarization phenotypes (69).
Therefore, because the PKC pathway has also been proposed to
be involved in polarization of the actin cytoskeleton, we do not
discard the possibility that mutations in WSC1 and ROM2
preadapt cells in some way that they become less prone to
depolarizing the actin cytoskeleton upon the appropriate envi-
ronmental signal(s). Further experiments will be needed to
clarify this point.
TOR function might not be actively inhibiting elements of
the PKC pathway. Instead, TOR function could be involved in
some aspects of cell wall integrity, and its failure would lead to
the activation of the PKC pathway provided cells are not os-
motically stabilized. However, the activation of cell surface
sensors probably does not respond to cell wall damage because
(i) Mpk1 activation by rapamycin treatment occurs in a very
short lapse of time, and it is difficult to explain how cell wall
architecture can be remodeled so rapidly; (ii) rapamycin-
treated cells become thermotolerant (6); and (iii) rapamycin-
treated cells are not more sensitive to zymoliase than
non-treated cells within the time course when the PKC signal-
ing is observed. Alternatively, TOR function may be involved in
the maintenance of an adequate outward osmotic pressure at
the plasma membrane. In this case, TOR inhibition would also
lead to the up-regulation of Mpk1 activity in a sorbitol-sup-
pressible manner. Support for this hypothesis is that (i) the
TOR proteins have been mainly localized to the plasma mem-
brane (70), where they could be involved in functions of the cell
envelope; and (ii) the simultaneous lack of Tor1 and Mpk1
function affects cell viability in a way suppressible by osmotic
stabilization. When cells are treated with rapamycin (as when
they enter stationary phase), the TOR shared function would
become blocked, giving rise to changes in the cell surface which
in turn would trigger actin cytoskeleton depolarization, Pkc1
up-regulation, and the concomitant induction of Mpk1 activity
and the expression of genes needed for cell wall construction.
Therefore, the latter signaling from TOR to the PKC pathway
is another cellular response to overcome or adapt to stressful
nutritional conditions and to prevent cell death.
We have also shown that the TOR effectors Sit4 and Tap42
mediate rapamycin signaling to Mpk1. Because rapamycin in-
duces the dissociation of the complex (6), this may lead to the
up-regulation of Mpk1 activity. The latter is in accordance with
the sit4 and tap42-11 mutant phenotypes: both of them block
rapamycin signaling to Mpk1 and up-regulate its basal activity
levels. Although speculative, this hypothesis suggests that the
tor1 strain may display higher basal levels of Mpk1 activity
because of lower TOR activity consequently reduced levels of
the Sit4-Tap42 complex. Therefore, we propose that the Sit4-
Tap42 complex may be the active form of Sit4 regarding the
rapamycin-sensitive regulation of the cell integrity pathway.
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Although we cannot exclude the possibility that Sit4 already
dissociated from Tap42 up-regulates the pathway, our previous
observations strongly suggest that this may not be the case
because SIT4 acts as a negative modulator of the cell integrity
pathway (33). The latter implies that in this signaling, Tap42
would act as a modulator of Sit4 rather than as an inhibitor.
This is in agreement with the observation that simultaneous
overexpression of SIT4 and TAP42 aggravates the growth de-
fects of the single overexpression mutants, suggesting that
TAP42 may activate SIT4 function(s) (6). These observations
are reflected in a model in which TOR proteins positively signal
to the Sit4-Tap42 complex, which in turn prevents (at least in
part) activation of cell surface sensors by inhibiting changes in
the yeast envelope (Fig. 7). Whether or not these changes mean
damage or just structural changes that do not affect the cell
wall resistance remains unclear. Another point we would like
to make is that we do not discard the possibility that the
Sit4-Tap42 complex might signal directly to other elements of
the cell integrity pathway, upstream from Pkc1 but down-
stream from cell wall sensors. Although rapamycin-mediated
activation of the PKC pathway is osmotically suppressible, we
have shown previously that Sit4 negatively modulates the ba-
sal activity of the pathway in a sorbitol-independent manner
and at a level downstream from cell surface sensors (33). Be-
sides, further activation of the PKC pathway in a sit4mutant
can be induced by heat shock, whereas this mutation renders
cells unable to induce Mpk1 by rapamycin (Ref. 33 and Fig. 2C).
This suggests that Sit4 may impinge on cell integrity regula-
tion via two different pathways. One involves Sit4 association
with Tap42 and is exercised at the level of the cell envelope.
The other one, which may not be necessarily related to rapa-
mycin signaling, operates upstream from Pkc1 to modulate the
activity of the MAPK module.
In mammalian cell lines, mTOR also controls several PKC
isotypes by promoting the phosphorylation of the kinases in
their hydrophobic C-terminal site (71, 72). This phosphoryla-
tion is rapamycin-sensitive, thus implying that mTOR posi-
tively regulates PKC phosphorylation in mammals. However,
the affected residue is different from the site phosphorylated by
phosphoinositide-dependent kinases in the activation loop of
PKC (for a recent review, see Ref. 73). Moreover, mTOR-de-
pendent phosphorylation has been proposed to be needed for
optimum PKC function. All of those putative phosphorylation
sites are conserved in yeast Pkc1, and phosphorylation by
phosphoinositide-dependent kinases, along with activation by
Rho1, plays an important role in regulating Pkc1 activity (74).
However, as we have shown above, a crucial difference arises in
yeast: contrary to what may occur in mammalian cells, the
TOR shared function negatively affects Pkc1 activity. Thus, it
seems that yeast and mammals have evolved different mecha-
nisms for TOR control over PKC activity.
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